Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol VEGFC contributors: mct - updated : 22-01-2015
HGNC name vascular endothelial growth factor C
HGNC id 12682
Location 4q34.3      Physical location : 177.604.690 - 177.713.895
Synonym name
  • vascular permeability factor VPFC
  • FLT4 ligand DHM
  • vascular endothelial growth factor-related protein
  • Synonym symbol(s) VPFC, Flt4-L, VRP, VEGF-C
    DNA
    TYPE functioning gene
    STRUCTURE 109.20 kb     7 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    MAPPING cloned Y linked N status confirmed
    RNA
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    7 - 2076 46.75 419 - 1997 9312130
    EXPRESSION
    Type widely
       expressed in (based on citations)
    organ(s)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Cardiovascularheart   highly
    Digestiveintestinesmall intestine  highly
    Endocrinepancreas   moderately
     thyroid   highly
    Reproductivefemale systemovary  highly
     female systemplacenta  highly
    Respiratorylung   moderately
     respiratory tracttrachea  lowly
    Skin/Tegumentskin   highly
    Urinarybladder   moderately
    tissue
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Blood / hematopoieticbone marrow  moderately
    Connective   moderately
    Muscularstriatumcardiac  
    cell lineage
    cell lines
    fluid/secretion
    at STAGE
    physiological period pregnancy
    Text placenta
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    motifs/domains
  • five cysteine-rich motifs
  • a platelet-derived growth factor (PDGF) domain
  • mono polymer homomer , dimer
    HOMOLOGY
    interspecies homolog to rattus Vegfc (85.54 pc)
    homolog to murine Vegfc (86.27 pc)
    Homologene
    FAMILY
  • PDGF/VEGF growth factor family
  • CATEGORY signaling growth factor
    SUBCELLULAR LOCALIZATION extracellular
        plasma membrane
    basic FUNCTION
  • involved in vasculogenesis
  • active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels
  • stimulating RANKL-mediated bone resorption
  • may have a role in the progressive growth and invasion of gallbladder cancer through an autocrine mechanism (
  • regulatory role of VEGFC in initiating and potentiating neo-angiogenesis, and does promote angiogenesis via RHOA mediated pathway
  • is a neurotrophic factor that influences the dopaminergic system through multiple mechanisms
  • macrophage-derived VEGFC activates FLT4 in tip cells to reinforce NOTCH signalling, which contributes to the phenotypic conversion of endothelial cells at fusion points of vessel sprouts
  • potential role of VEGFC in the pathogenesis and development of a conjonctival pterygium through lymphangiogenesis
  • FAS and NFKB play a role in the initiation and development of breast cancer, while VEGFC appears to promote lymph node metastasis
  • important for angiogenesis in endometriosis
  • FLT4 with its cognate ligand vascular endothelial growth factor C (VEGFC), is a major mediator of lymphangiogenesis
  • acts primarily on endothelial cells, but also on non-vascular targets, for example in the CNS and immune system
  • CELLULAR PROCESS cell life, differentiation
    cell life, proliferation/growth
    PHYSIOLOGICAL PROCESS cardiovascular , angiogenesis
    PATHWAY
    metabolism
    signaling signal transduction
  • VEGFC/FLT4 signaling pathway is essential for lymphangiogenesis (the formation of lymphatic vessels from pre-existing vasculature) during embryonic development, tissue regeneration and tumor progression
  • a component
  • RSPO1-WNT-VEGFC-FLT4 signaling plays a crucial role as an endothelial-autonomous permissive cue for developmental angiogenesis
  • INTERACTION
    DNA
    RNA
    small molecule
    protein
  • high affinity for both KDR (VEGFR2) and FLTR (VEGFR3)
  • ligand of FLT4
  • NRP2 is a transmembrane receptor for the lymphangiogenic vascular endothelial growth factor C (VEGFC), plays an important role in lymphatic vessel sprouting
  • interaction between NRP2 and FLT4 mediates proper lymphatic vessel sprouting in response to VEGFC
  • CYR61 modulates the VEGFC expression of decidual natural killer cells via PI3K/AKT pathway
  • EDN1 is potent lymphangiogenic factor that relies on the interplay with hypoxic microenvironment and with VEGFA, VEGFC, and FIGF (PMID;
  • VEGFC and FIGF play a role in the induction of osteoclast differentiation through both KDR and FLT4 receptors (
  • VEGFC and its receptor FLT4 mediate lymphangiogenesis
  • in the tumor microenvironment, the reciprocal interplay between FGF2 and VEGFC collaboratively stimulated tumor growth, angiogenesis
  • PTGS2 and and VEGFC are inducers of lymphangiogenesis and their expression levels were correlated in non-Hodgkin lymphoma
  • CAPN2 may contribute to the promoter methylation of DPYSL3 to repress its transcription, leading to the metastasis of Prostate carcinoma via enhancing VEGFC expression
  • cathepsin D is a protease that can activate VEGFC as well as FIGF
  • cell & other
    REGULATION
    activated by KLK3 (KLK3 activated VEGFC specifically and efficiently through cleavage at a novel N-terminal site)
    induced by hypoxia-inducible
    TGFB1
    repressed by downregulated by VHL
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in vascular invasion, involving lymphatic vessels and lymph node, distant metastasis and poor clinical outcomes
    constitutional     --over  
    in eutopic and ectopic endometrium of endometriosis patients
    tumoral     --low  
    in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms
    tumoral     --over  
    of VEGFC and FIGF correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer (
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancer  
    high potentiality of VEGFC as a cancer drug target
    ANIMAL & CELL MODELS